Metastatic Breast Cancer News
- New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective ... Tue, 02 Dec 2008 07:00:00 -0600 InSightec Ltd. announced today that new publications show that Magnetic Resonance-guided Focused Ultrasound with the ExAblate® system has the potential to be an effective noninvasive pain-relieving treatment for tumors that have spread to the bones .
- Cytokinetics Announces Clinical Trial Data Regarding SB-743921 to Be Presented at the 2008 American Society of ... Mon, 01 Dec 2008 15:00:00 -0600 Cytokinetics, Incorporated announced today that an abstract summarizing interim clinical trial data evaluating SB-743921 is scheduled to be presented as a poster presentation at the 2008 American Society of Hematology Annual Meeting and Exposition to be held December 6-9, 2008 at the Moscone Center in San Francisco, California.
- Health & Fitness Calendar Mon, 01 Dec 2008 00:05:53 -0600Free Exercise Sessions for Children: 4:45-6 p.m. today through Thursday for ages 8-13 at Prairie Life Fitness Center, 3690 S. Houston Levee in Collierville.
- 03.12.2008 - DJ HUGIN NEWS/Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented ... Wed, 03 Dec 2008 06:46:59 -0600Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. =--------------------------------------------------------------------- =-------------
- Cytokinetics to Present at the RBC Capital Markets Healthcare Conference Wed, 03 Dec 2008 15:00:00 -0600 Cytokinetics, Incorporated announced today that Sharon Barbari, Senior Vice President, Finance and Chief Financial Officer, is scheduled to participate in a panel discussion entitled "Replacing The Mainstay With Newer And Better Agents" at the RBC Capital Markets 2008 Healthcare Conference on Wednesday, December 10, 2008 at 4:30 p.m.
- Bevacizumab Associated With Increased Venous Thromboembolism Sun, 30 Nov 2008 17:04:40 -0600Bevacizumab, a cancer drug, may be associated with an increased risk of venous thromboembolism, according to an analysis of several randomized controlled trials released on November 19, 2008 in JAMA. When a cancer forms, it necessarily undergoes the process of angiogenesis, whereby new blood vessels proliferate into the tumor.
- More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current ... Thu, 04 Dec 2008 00:25:00 -0600 Tasigna front-line data demonstrating potential in newly diagnosed patients with a life-threatening type of leukemia to be featured in two oral sessions at ASH
- Micromet Expands Committed Equity Financing Facility to $75 Million Tue, 02 Dec 2008 06:00:00 -0600 Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it has entered into an agreement expanding its Committed Equity Financing Facility with Kingsbridge Capital Limited, a private investment group.
- Behavior And Screening Have Biggest Impact On Drop In Cancer Deaths Wed, 03 Dec 2008 10:22:31 -0600Improvements in behavior and screening have contributed greatly to the 13 percent decline in cancer mortality since 1990, with better cancer treatments playing a supporting role, according to new research from David Cutler of Harvard University. While not the first to report a long-term decline in cancer mortality, Cutler's is the first study to examine the reasons for this decline.
- Are we finally winning the war on cancer? Wed, 03 Dec 2008 04:29:39 -0600Improvements in behavior and screening have contributed greatly to the 13 percent decline in cancer mortality since 1990, with better cancer treatments playing a supporting role, according to new research from David Cutler of Harvard University.
- Drop In Cancer Deaths Tied Primarily To Gains In Behavior And Screening Tue, 02 Dec 2008 16:29:03 -0600Behavior change and improvements in screening have contributed equally and substantially to the 13 percent decline in cancer mortality rates, according to new research. Cancer treatment after diagnosis has also contributed to the decline, although this is less of a factor than behavioral changes and screening.
- Drop in cancer deaths tied primarily to gains in behavior and screening Tue, 02 Dec 2008 10:55:08 -0600( Harvard University ) Behavior change and improvements in screening have contributed equally and substantially to the 13 percent decline in cancer mortality rates, according to new research from David Cutler, an economist at Harvard University. Cancer treatment after diagnosis has also contributed to the decline, although this is less of a factor than behavioral changes and screening.
- New Phase III Study Of Avastin In Advanced Breast Cancer Meets Its Primary Endpoint Of Increasing The Time Patients Live Fri, 28 Nov 2008 07:06:51 -0600Third study confirming the benefit of Avastin in breast cancer shows that Avastin can be effectively combined with commonly used chemotherapies Roche announced that the Avastin study RIBBON-1 met its primary endpoint of increasing the time women with breast cancer lived without their disease advan
- Celgene Corporation and Acceleron Pharma to Present ACE-011 Data at the 50th Annual Meeting of the American Society of ... Wed, 03 Dec 2008 06:30:00 -0600 CAMBRIDGE, Mass.----Celgene Corporation and Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that results from preclinical and clinical studies of ACE-011 will be presented at the annual meetings of the American Society of Hematology and the San Antonio Breast Cancer Symposium over a ...
- Anavex presents potent neuroprotective effects of Anavex 1-41 at Neuroscience 2008 Thu, 04 Dec 2008 08:00:00 -0600 Anavex Life Sciences Corp. , a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System diseases and cancer, was selected to present its latest results with ANAVEX 1-41 at Neuroscience 2008, the 38th annual meeting of the Society for Neuroscience, which took place November 15-19, 2008 in Washington, DC.
- OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study Wed, 03 Dec 2008 05:00:00 -0600 line trial currently shows median overall survival of 27.5 months
- Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of ... Wed, 03 Dec 2008 06:00:00 -0600 Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, will host a webcast and conference call on, Monday, December 8, 2008, at 2:00 p.m.
- OGX-011 Shows Overall Survival Advantage In Prostate Cancer Compared To Standard Therapy In A Randomized Phase 2 Study Wed, 03 Dec 2008 13:05:41 -0600OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced positive survival results from a randomized Phase 2 clinical trial of OGX-011 in combination with docetaxel and prednisone ("the OGX-011 arm") compared to docetaxel and prednisone alone ("the control arm") for first-line treatment of metastatic castrate resistant prostate cancer. The current 10.
- Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a ... Wed, 03 Dec 2008 06:00:00 -0600 Isis Pharmaceuticals, Inc. announced today that OncoGenex Pharmaceuticals, Inc. provided positive survival results from a randomized Phase 2 clinical trial of OGX-011 in combination with docetaxel and prednisone compared to docetaxel and prednisone alone for first-line treatment of metastatic castrate resistant prostate cancer.
- OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study Wed, 03 Dec 2008 05:00:00 -0600 OncoGenex Pharmaceuticals, Inc. today announced positive survival results from a randomized Phase 2 clinical trial of OGX-011 in combination with docetaxel and prednisone compared to docetaxel and prednisone alone for first-line treatment of metastatic castrate resistant prostate cancer.
- Free yoga classes are for all skill levels Thu, 04 Dec 2008 03:55:33 -0600The Louisville Metro Department of Public Health and Wellness is offering free yoga classes from 5:15 to 6:15 p.m. today, next Thursday and Dec. 18 at the Center for Health Equity, 2422 W. Chestnut St. The classes are open to the general public and to those of all ability levels.
- Curbing hormones' effects in obese patients could aid against breast cancer Mon, 01 Dec 2008 16:36:39 -0600Once-promising drugs that were abandoned in the fight against breast cancer still could be effective in obese patients, new research suggests.
- Isis Announces That OGX-011 Has Shown Overall Survival Advantage In Prostate Cancer Compared To Standard Therapy In A ... Thu, 04 Dec 2008 05:20:31 -0600Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that OncoGenex Pharmaceuticals, Inc. provided positive survival results from a randomized Phase 2 clinical trial of OGX-011 in combination with docetaxel and prednisone ("the OGX-011 arm") compared to docetaxel and prednisone alone ("the control arm") for first-line treatment of metastatic castrate resistant prostate cancer. The current 10.
- Curbing Hormones' Effects In Obese Patients Could Aid Against Breast Cancer Tue, 02 Dec 2008 11:20:32 -0600Once-promising drugs that were abandoned in the fight against breast cancer still could be effective in obese patients, new research suggests. In laboratory tests, hormones produced by fat cells stimulate breast cancer cells to migrate and invade surrounding tissues, scientists at Emory University School of Medicine found.
- On the Move With a New Breast Cancer Resource Wed, 03 Dec 2008 18:54:07 -0600(ARA) - When a woman is first diagnosed with breast cancer, all kinds of questions go through her mind, and not all of them are about the cancer itself. "Will I be able to remain active? What kind of impact will treatment have on my lifestyle? Can I still be intimate with my significant other?"
- Curbing Hormones' Effects In Obese Patients Could Aid Against Breast Cancer Wed, 03 Dec 2008 13:14:14 -0600Results from cell culture studies suggest a class of anticancer compounds called EGFR inhibitors, largely written off for breast cancers, could be effective in obese patients. The hormones leptin and IGF-1 synergistically stimulate migration and invasion in breast cancer cells. EGFR inhibitors block this stimulation.
- BiPar Sciences to Present At the 31st CTRC-AACR Annual San Antonio Breast Cancer Symposium Thu, 04 Dec 2008 08:30:00 -0600 BRISBANE, Calif., Dec. 4, 2008 -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that the company's lead PARP product candidate for triple negative breast cancer, BSI-201, will be the subject of a poster presentation at the 2008 annual San Antonio Breast Cancer Symposium .
- Drug fights one type of breast cancer Thu, 04 Dec 2008 13:15:51 -0600 LOS ANGELES, Dec. 4 (UPI) -- A breast cancer chemotherapy drug shows benefits in fighting one type of breast cancer but not another type, U.S. researchers say.
- Chemo drug aids one type of breast cancer Thu, 04 Dec 2008 12:45:23 -0600 LOS ANGELES, Dec. 4 (UPI) -- A breast cancer chemotherapy drug shows benefits to one type of breast cancer but not for another type, U.S. researchers said.
- HER2 Levels May Aid In Treatment Selection For Metastatic Breast Cancer Wed, 03 Dec 2008 11:05:48 -0600Findings published in the December 1, 2008, issue of Clinical Cancer Research , a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit.
- HER2 levels may aid in treatment selection for metastatic breast cancer Tue, 02 Dec 2008 09:42:49 -0600( American Association for Cancer Research ) Findings published in the Dec. 1, 2008, issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit. In addition, a misclassification of metastatic ...
- HER2 may be key in treating metastatic breast cancer Thu, 04 Dec 2008 02:33:07 -0600PHILADELPHIA – Dec. 3, 2008 – Women with HER2-positive breast cancer benefit from lapatinib (TYKERB®), while women with HER2-negative breast cancer gain no incremental benefit, a new study shows.
- HER2 levels may aid in treatment selection for metastatic breast cancer Tue, 02 Dec 2008 11:50:39 -0600Findings published in the December 1, 2008, issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit. In addition, a misclassification of metastatic breast cancer patients by as much as 10 ...
